Artificial intelligence is transforming medicine, but what does that mean for breast cancer screening? Researchers at UMass Chan Medical School are exploring how an AI-based tool might help identify ...

One way cancer specialists detect the disease is by examining cells and bodily fluids under a microscope, a time-consuming ...

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announced it will present 14 studies at the Radiological Society ...

Tempus AI, Inc. TEM recently announced a collaboration with Median Technologies to integrate Median’s proprietary eyonis LCS solution into the Tempus Pixel platform. The integration is expected to ...

Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed at improving cancer diagnostics. The company has entered a partnership with Median Technologies to bring advanced lung ...

Beth Israel Deaconess Medical Center on Friday rolled out an AI-driven technology that detects the risk of developing breast cancer in the next five years. Why it matters: The Clairity Breast platform ...

Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...

Researchers have developed an electronic nose that can “smell” early signs of ovarian cancer in the blood. The method is precise and could eventually be used to find many different cancers.

The U.S. Food and Drug Administration (FDA) has approved the first artificial intelligence (AI) tool to predict breast cancer risk. The authorization was confirmed by digital health tech company ...

Tempus AI recently reported full-year 2025 results, with revenue rising to US$1.27 billion and net loss narrowing to US$245.03 million, alongside 83% year-over-year Q4 growth driven by diagnostics. At ...

Making healthier choices is hard. But it’s also something that AI is uniquely positioned to solve, write Sam Altman and ...